• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Lat­est news: Am­gen's land­mark OK for KRAS drug, in­side Ver­tex 3.0, the big hunt for CAR-T in sol­id tu­mors, and more

Last year
Weekly

Am­gen cracks the un­drug­gable code, earn­ing the FDA's nod for first-ever KRAS in­hibitor

Last year
Pharma
FDA+

Bris­tol My­ers gets its first GI drug ap­proval, and it comes from a long­time Cel­gene MS pro­gram

Last year
FDA+

FDA ad­comm votes in fa­vor of ap­prov­ing Proven­tion Bio’s drug to de­lay type 1 di­a­betes

Last year
Pharma
FDA+

Alise Re­icin re­cruits GNF vet Pe­ter Mc­Na­ma­ra to head re­search at Tim Springer's lat­est start­up

Last year
People
R&D

FDA steers J&J/Leg­end CAR-T to a quick de­ci­sion as part­ners prep a loom­ing show­down with Bris­tol My­ers, blue­bird

Last year
Cell/Gene Tx
FDA+

No­vo Hold­ings, Vi­vo lead a record $200M raise for a Sin­ga­pore-based tools play­er with plans for a Boston hub, new deals

Last year
Financing
China

FDA au­tho­rizes Vir-GSK an­ti­body as vari­ants threat­en Eli Lil­ly mAb

Last year
R&D
Coronavirus

Opin­ion: It shouldn’t mat­ter who the FDA com­mis­sion­er is when it comes to con­tro­ver­sial drug ap­proval de­ci­sions

Last year
FDA+
Opinion

Un­der-the-radar NiKang Ther­a­peu­tics bursts on­to the scene with $200M Se­ries C from in­vestors that screams IPO

Last year
Financing

Omid Farokhzad’s biotech in­sid­ers SPAC opens the deal win­dow with $200M to play with

Last year
Financing

Deaths of mon­keys spur clin­i­cal hold for rare dis­ease biotech's lead and on­ly drug — and a $95M cash in­fu­sion goes out the win­dow

Last year
FDA+

Black­stone en­lists a mur­der­ers' row of ad­vi­sors, in­clud­ing ex-Sanofi CEO Olivi­er Brandi­court, to steer life sci­ences biz

Last year
People
Financing

Pieris inks res­pi­ra­to­ry part­ner­ship with Genen­tech, adding an­oth­er to slate of mile­stone-heavy deals

Last year
Deals

The $70B ques­tion: What’s Pfiz­er go­ing to do with all that Covid vac­cine cash?

Last year
Deals
Bioregnum

Ab­b­Vie’s last stand: How an Ice­landic bil­lion­aire’s biosim­i­lar has one fi­nal shot to de­throne Hu­mi­ra

Last year
Pharma

Boehringer em­barks on a PhI­II odyssey for a failed Alzheimer's drug — now re­fo­cused on schiz­o­phre­nia with new tri­al tech and a ‘break­through’ at the FDA

Last year
R&D

Bi­par­ti­san House bill seeks new $30B ‘BioBonds’ loan pro­gram to rein­vig­o­rate clin­i­cal tri­als

Last year
Financing
R&D

NGM con­cedes key fail­ure for their lead NASH drug, clos­ing the door on a piv­otal fol­lowup — and ask­ing an­a­lysts to look past the wreck­age in­to the pipeline

Last year
R&D

Lat­est news on J&J’s NSCLC ap­proval, Bris­tol My­ers Squibb’s big TIG­IT bet, #AS­CO21 and more

Last year
Weekly

CVS splash­es in­to clin­i­cal tri­al ser­vices, lean­ing on lo­cal roots to change the game in terms of pa­tient en­gage­ment

Last year
Outsourcing

Arie Bellde­grun's vi­sion for Gink­go comes in­to view, as the now $15B com­pa­ny teams with Bio­gen on gene ther­a­py

Last year
Deals

No­var­tis' San­doz reshuf­fles an­tibi­ot­ic sup­ply chain in EU as field faces a short­age of in­vest­ment

Last year
Manufacturing

House com­mit­tee grills Emer­gent CEO Bob Kramer over J&J vac­cine de­ba­cle, ill-timed stock sale

Last year
People
R&D
First page Previous page 118119120121122123124 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET